ABVC — ABVC Biopharma Share News
0.000.00%
Last trade - 00:00Abvc Biopharma Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: ABVC BioPharma Reports Q2 2022 Results
Abvc Biopharma Inc Expected To Post A Loss Of 20 Cents A Share: Earnings Preview
Brief: ABVC BioPharma Says Phase II Vitargus Clinical Study Protocol Gets Local Ethics Committee Approval
Brief: ABVC Biopharma Provides Vitargus Update
Development Partnership With Rgene Corporation
Brief: ABVC Biopharma Submits Vitargus Phase II Study Plan To Australia HREC
Brief: Abvc Biopharma Announces Termination Of Two Contracts
Brief: ABVC Biopharma Announces Enrollment Progress For ADHD Phase II Part 2 Clinical Study
Brief: ABVC BioPharma Engaged by Orion BioTech To Identify Global Licensing Partners
Brief: ABVC Biopharma Reports First Quarter 2022 Financial And Operational Results
Brief: WallachBeth Capital Announces Pricing Of ABVC Biopharma $4.22 Million Registered Direct Offering
Brief: ABVC Biopharma Announces $4.22 Million Registered Direct Offering
Brief: ABVC Biopharma ADHD Phase II Part 2 Clinical Study First Subject Treated
Brief: ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process
Brief: Abvc Biopharma Enters Into $3.0 Million Clinical Services Contract With Neucen Biomed
Brief: ABVC Biopharma Completes Site Initiation Visits And Begins Enrollments For Adhd Phase Ii Part 2 Clinical Study
Brief: ABVC BioPharma Reports Vitargus Phase II Clinical Study Investigator Meeting
Brief: ABVC Biopharma Announces Fiscal Year 2021 Financial And Operational Results